FINWIRES · TerminalLIVE
FINWIRES

RemeGen Gets Marketing Nod for Sjögren's Syndrome Drug in China

By

RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and marketing approval for a new indication of Telitacicept for Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.

The new indication of the drug is for the treatment of Sjögren's syndrome, the biopharmaceutical company said.

Related Articles